Influenza Division, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Center for Vaccine Equity, Task Force for Global Health, Atlanta, GA, USA.
Influenza Division, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Vaccine. 2019 Aug 14;37(35):5089-5095. doi: 10.1016/j.vaccine.2019.06.049. Epub 2019 Jul 6.
Influenza vaccination remains the most effective tool for reducing seasonal influenza disease burden. Few Low and Middle-Income Countries (LMICs) have robust, sustainable annual influenza national vaccination programs. The Partnership for Influenza Vaccine Introduction (PIVI) was developed as a public-private partnership to support LMICs to develop and sustain national vaccination programs through time-limited vaccine donations and technical support. We review the first 5 years of experience with PIVI, including the concept, country progress toward sustainability, and lesson learned. Between 2013 and 2018, PIVI worked with Ministries of Health in 17 countries. Eight countries have received donated vaccines and technical support; of these, two have transitioned to sustained national support of influenza vaccination and six are increasing national support of the vaccine programs towards full transition to local vaccine program support by 2023. Nine additional countries have received technical support for building the evidence base for national policy development and/or program evaluation. PIVI has resulted in increased use of vaccines in partner countries, and early countries have demonstrated progress towards sustainability, suggesting that a model of vaccine and technical support can work in LMICs. PIVI expects to add new country partners as current countries transition to self-reliance.
流感疫苗接种仍然是减轻季节性流感疾病负担的最有效工具。少数中低收入国家（LMICs）拥有强大、可持续的年度流感国家疫苗接种计划。伙伴关系推进流感疫苗引入（PIVI）是作为公私合作伙伴关系建立的，旨在通过有限期的疫苗捐赠和技术支持，支持 LMICs 制定和维持国家疫苗接种计划。我们回顾了 PIVI 的头 5 年经验，包括概念、国家向可持续性发展的进展以及经验教训。2013 年至 2018 年，PIVI 与 17 个国家的卫生部合作。8 个国家收到了捐赠的疫苗和技术支持；其中，有两个国家已过渡到可持续的国家流感疫苗接种支持，另外 6 个国家正在增加对疫苗计划的国家支持，以便到 2023 年全部过渡到地方疫苗计划支持。另外 9 个国家收到了为制定国家政策和/或方案评估建立证据基础的技术支持。PIVI 促使合作伙伴国家增加了疫苗的使用，并且早期国家已经在可持续性发展方面取得了进展，这表明疫苗和技术支持模式在 LMICs 中是可行的。随着当前国家向自给自足过渡，PIVI 预计将增加新的国家合作伙伴。
